Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Kimberley Dilley, MD MPH, Jason Harb, PhD, Muhammad Jalaluddin, PhD, Jessica E. Hutti, PhD, Jalaja Potluri, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-139247

Published: 2020

Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-134850

Published: 2020

Journal Articles

Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Doerthe Eckert, MSc, Deanna Brackman, PhD, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD FCP, Jalaja Potluri, MD, B. Douglas Smith, MD, Andrew H. Wei, John Hayslip, MD MSCR, Dale Miles, PhD, Sven Mensing, PhD, Sathej Gopalakrishnan, PhD, Jiuhong Zha, PhD

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-136425

Published: 2020

Journal Articles

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)

Jalaja Potluri, MD, Jason Harb, PhD, Abdullah A. Masud, PhD, Jessica E. Hutti, PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-139758

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Daniel A. Pollyea, Courtney D. Dinardo, MDMSc, Martha L. Arellano, MD, Arnaud Pigneux, MD PhD, Walter Fiedler, MD, Marina Konopleva, MD PhD, David A Rizzieri, MD, B. Douglas Smith, MD, Atsushi Shinagawa, MD PhD, Roberto M. Lemoli, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Jean A Ridgeway, DNP, NP-C, Hagop M. Kantarjian, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-134736

Published: 2020

Journal Articles

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Jacqueline S. Garcia, MD, Jalaja Potluri, MD, Leanne Holes, BS, MBA,, Jason Harb, PhD, Paul Jung, PhD, Jessica E. Hutti, PhD, Josef T. Prchal, MD, Srdan Verstovsek, MD PhD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-136938

Published: 2020

Journal Articles

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-133912

Published: 2020

Journal Articles

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Marina Konopleva, MD PhD, Michael Thirman, MD, Keith W. Pratz, MD, Anthony G. Letai, MD PhD, Christian Recher, MD PhD, Vinod A. Pullarkat, MD, Hagop M. Kantarjian, MD, Monique Dail, PhD, Yinghui Duan, PhD, Brenda J. Chyla, Jalaja Potluri, MD, Catherine Miller, PharmD, Courtney D. Dinardo, MDMSc, Andrew H. Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134100

Published: 2020

Journal Articles

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Blood (2020) 136 (Supplement 1): 51–53.

https://doi.org/10.1182/blood-2020-134832

Published: 2020

Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip

Blood (2019) 134 (Supplement_1): 546.

https://doi.org/10.1182/blood-2019-128373

Published: 2019

Journal Articles

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSc, Martha L. Arellano, MD, Anthony G. Letai, MD PhD, Michael Thirman, MD, Vinod A. Pullarkat, MD, Gail J. Roboz, MD, Pamela S. Becker, MD PhD, Wan-Jen Hong, MD, Qi Jiang, John Hayslip, MD MSCR, Jalaja Potluri, MD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 264.

https://doi.org/10.1182/blood-2019-127251

Published: 2019

Journal Articles

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Keith W. Pratz, MD, Andrew H. Wei, Daniel A Pollyea, MD, Brian A Jonas, MD PhD, Walter Fiedler, MD, Christian Recher, MD PhD, Wan-Jen Hong, MD, Jalaja Potluri, MD, Catherine Miller, PharmD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3897.

https://doi.org/10.1182/blood-2019-127423

Published: 2019

Journal Articles

Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Suresh Agarwal, PhD, Sathej Gopalakrishnan, PhD, Sven Mensing, PhD, Jalaja Potluri, MD, John Hayslip, Anna Friedel, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD

Blood (2018) 132 (Supplement 1): 5239.

https://doi.org/10.1182/blood-2018-99-116790

Published: 2018

Journal Articles

Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

Daniel A Pollyea, MD, Keith W. Pratz, MD, Brian A. Jonas, MD, Anthony Letai, MD PhD, Vinod A. Pullarkat, MD, Andrew Wei, MD, Marina Y. Konopleva, MD PhD, Christian Recher, MD PhD, Olga Frankfurt, MD, David Rizzieri, MD, Tu Xu, PhD, Monique Dail, Brenda Chyla, Jalaja Potluri, MD, Courtney D. DiNardo, MDMSc

Blood (2018) 132 (Supplement 1): 285.

https://doi.org/10.1182/blood-2018-99-117179

Published: 2018

Journal Articles

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G. Wierda, MD PhD, Andrew W. Roberts, MBBS, PhD, Paolo Ghia, MD PhD, Jennifer R. Brown, MD PhD, Stephan Stilgenbauer, Florence Cymbalista, MD, Nicole Lamanna, MD, John F. Seymour, MBBS, PhD, Sebastian Böttcher, MD, Madlaina Breuleux, PhD DAS, Brenda Chyla, Lang Zhou, PhD, Jacqueline Nielsen, PhD, Su Young Kim, MD PhD, Jalaja Potluri, MD, Johnathan C. Maher, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3134.

https://doi.org/10.1182/blood-2018-99-110183

Published: 2018

Journal Articles

Transfusion Requirements and Hospitalization during First Line Treatment Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Were Ineligible for Intensive Chemotherapy

Cat N. Bui, PhD, Thomas Marshall, PharmD, MS, Rajesh Kamalakar, MS, Tracey Posadas, PharmD, MPH, Jalaja Potluri, MD

Blood (2018) 132 (Supplement 1): 4849.

https://doi.org/10.1182/blood-2018-99-117247

Published: 2018

Journal Articles

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Courtney D. DiNardo, MDMSc, Daniel A. Pollyea, MD, Brian A Jonas, MD PhD, Marina Konopleva, MD PhD, Vinod Pullarkat, MD MRCP, Andrew Wei, MBBS, PhD FRACP, FRCPA, Hagop M. Kantarjian, MD, Arnaud Pigneux, MD PhD, Christian Recher, MD PhD, John F Seymour, MB BS PhDFRACP, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Keith Pratz, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 2628.

https://doi.org/10.1182/blood.V130.Suppl_1.2628.2628

Published: 2017

Journal Articles

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

Jeffrey Jones, MD, Anthony R. Mato, MD, Steven Coutre, MD, William Wierda, MD PhD, Michael Y. Choi, MD, Matthew S. Davids, MD, Nicole Lamanna, MD, Paul Barr, MD, Kim Burns, BA, Nicholas Montalvo, MBA, Ming Zhu, PhD, Todd Busman, MS, Jalaja Potluri, MD FACP, Rod A. Humerickhouse, MD PhD, John C. Byrd, MD

Blood (2015) 126 (23): 715.

https://doi.org/10.1182/blood.V126.23.715.715

Published: 2015

Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 327.

https://doi.org/10.1182/blood.V126.23.327.327

Published: 2015

Journal Articles

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Blood (2014) 124 (21): 118.

https://doi.org/10.1182/blood.V124.21.118.118

Published: 2014

NARROW

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based Therapies

Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia

Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

Transfusion Requirements and Hospitalization during First Line Treatment Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Were Ineligible for Intensive Chemotherapy

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia

Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only